Please login to the form below

Not currently logged in
Email:
Password:

hypertension

This page shows the latest hypertension news and features for those working in and with pharma, biotech and healthcare.

NHS England says yes to Roche's Hemlibra

NHS England says yes to Roche's Hemlibra

One product which was refused reimbursement in the process was Actelion’s pulmonary arterial hypertension (PAH) treatment Uptravi (selexipag.

Latest news

More from news
Approximately 14 fully matching, plus 274 partially matching documents found.

Latest Intelligence

  • Reading human behaviour to create a medical future Reading human behaviour to create a medical future

    improve. “Now, we are now at a stage where the biggest causes of morbidity and mortality are diabetes, obesity, CVD and hypertension and autoimmune conditions which require significant self-management, so

  • Tools for the digital world Tools for the digital world

    One study showed that patients with uncontrolled hypertension and diabetes achieved significantly greater reduction in blood pressure (BP) and LDL cholesterol, and were more likely to reach their BP goal, than

  • Proving real-world value Proving real-world value

    Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”.

  • Is it time we stopped talking about adherence? Is it time we stopped talking about adherence?

    The EarthWorks has employed this philosophy to develop award-winning patient support programmes in chronic conditions such as asthma and HIV, and rare, complex conditions such as pulmonary arterial hypertension.

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia - would generate cost-savings in excess of £500m a year. ... were able to identify those with uncontrolled hypertension due to medication non

More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).

  • New associate director at Packer Forbes New associate director at Packer Forbes

    Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

  • Three directors join UK’s MHRA Three directors join UK’s MHRA

    His research has focused on internal medicine, hypertension and cardiovascular risk management, and he established Edinburgh University's Wellcome Trust cardiovascular research initiative and centre for cardiovascular science.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Barber shops provide a short cut to BP reduction

    Barber shops provide a short cut to BP reduction. 44 (0) 1344 899050. Address:. Life Healthcare Communications. The Hernes Oak. North Street. Winkfield. Windsor. SL4 4SY.

  • 6 Ways to Make MROC’s Rock

    stand on your head, say cheese and record a video of yourself decanting your pills into a box may not yield the best understanding of how hypertension medication is managed at

  • Packer Forbes News January 2016

    year. Amy is looking forward to working on a range of therapy areas including pulmonary arterial hypertension and HIV.

  • Ageing in China: The Implications for Healthcare

    According to a recent survey, there are 62 million elderly experiencing body pain and 100 million having hypertension.

  • 6 things that doctors want

    adherence conditions like hypertension– perhaps by prompting patients to follow the prescription or lifestyle advice.What’ s key is that technology must make the treatment meaningful to patients.

More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics